Panbela Therapeutics (PBLA) AI Stock Analysis

• Market Cap: $53.89K
• Dividend Yield: N/A
• Average Volume (3M): 4.36K
• Price to Earnings (P/E): ―
• Beta (1Y): -4.04
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 4,854,831
• 10 Day Avg. Volume: 549
• 30 Day Avg. Volume: 4,356
• PEG Ratio: >-0.01
• Price to Book (P/B): -12.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.27
• Enterprise Value/Market Cap: 49.54
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.09
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: ―
• Action: N/A Date: 01/31/25
• Date: Action: N/A 01/31/25

Panbela Therapeutics faces significant financial instability, with no revenue and negative equity, which are major concerns. While there are positive developments in clinical trials and strategic investments, the ongoing financial challenges and reliance on external funding heavily weigh down the score. The technical indicators and valuation metrics provide little support, reflecting limited investor confidence.

Positive Factors

Strategic Investment

This investment demonstrates confidence in Panbela's approach and provides crucial financial support, enabling continued R&D and clinical trials.

Clinical Trial Progress

Progress in the ASPIRE trial suggests potential improvements in patient outcomes, enhancing Panbela's competitive position in cancer treatment.

FDA Approval

FDA approval of eflornithine validates Panbela's polyamine-focused approach, potentially opening new revenue streams and enhancing market credibility.

Negative Factors

Financial Instability

Ongoing financial losses highlight significant operational challenges and reliance on external funding, which may impact long-term viability.

Cash Flow Concerns

Low cash reserves indicate potential liquidity issues, necessitating continuous external funding to sustain operations and strategic initiatives.

Negative Equity

Negative equity reflects financial instability, posing a risk of insolvency and limiting the company's ability to secure favorable financing terms.

Panbela Therapeutics Business Overview & Revenue Model

Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

How the Company Makes Money

Panbela Therapeutics generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company invests heavily in research and development to bring its innovations from the lab to the market. Potential revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments based on the achievement of clinical and regulatory benchmarks, and future sales of approved therapies. Panbela may also receive funding through strategic partnerships, grants, and potential collaborations with academic and research institutions dedicated to cancer treatment advancements. As these therapies progress through clinical trials and regulatory approvals, Panbela aims to establish a robust market presence and generate significant revenue from the commercial distribution of its products.

Panbela Therapeutics Financial Statement Overview

Summary

Panbela Therapeutics is facing significant financial challenges with no revenue and consistent losses, leading to negative equity and a reliance on financing for cash flow. The biotechnology industry often requires substantial investment before profitability; however, the current trajectory highlights significant financial instability and risk.

Income Statement

Panbela Therapeutics has consistently reported negative gross profit, EBIT, and net income over the past several years, with no revenue generated. This indicates a challenging financial position with high operational costs and no income to offset these expenses. The company lacks revenue growth, which is crucial for financial improvement.

Balance Sheet

The company's balance sheet shows negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, posing a risk of insolvency. The equity ratio is also negative, reflecting weak financial stability.

Cash Flow

Panbela Therapeutics has negative free cash flow, suggesting it is not generating enough cash to sustain operations and relies heavily on financing activities. However, the company has maintained some cash flow through financing, which indicates a potential to manage short-term liquidity needs.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-29.04M	-25.65M	-35.73M	-10.01M	-5.75M	-4.32M
EBITDA	-26.40M	-51.29M	-34.74M	-10.61M	-5.05M	-4.42M
Net Income	-27.91M	-25.26M	-34.93M	-10.13M	-4.77M	-6.20M
Balance Sheet
Total Assets	5.17M	11.80M	4.98M	12.87M	9.81M	3.14M
Cash, Cash Equivalents and Short-Term Investments	142.00K	2.58M	1.28M	11.87M	9.02M	2.45M
Total Debt	6.39M	5.19M	6.84M	0.00	0.00	116.00K
Total Liabilities	23.34M	16.51M	13.03M	2.66M	1.36M	1.76M
Stockholders Equity	-18.17M	-4.71M	-8.05M	10.21M	8.45M	1.39M
Cash Flow
Free Cash Flow	-15.57M	-25.25M	-15.94M	-6.70M	-3.85M	-2.74M
Operating Cash Flow	-15.57M	-25.25M	-15.28M	-6.70M	-3.85M	-2.74M
Investing Cash Flow	-7.97M	400.00K	-656.00K	-540.00K	0.00	0.00
Financing Cash Flow	14.03M	26.14M	5.35M	10.10M	10.44M	3.78M

Panbela Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBLA, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.61 is Neutral, neither overbought nor oversold. The STOCH value of -3.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBLA.

Panbela Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	49 Neutral	$732.72K	-0.07	―	―	178.82%	-4121.10%
BDRX	41 Neutral	$693.87K	-0.02	-60.37%	―	-100.00%	86.75%
PBLA	37 Underperform	$53.89K	―	―	―	―	―
OGEN	29 Underperform	$2.94M	-0.05	-168.95%	―	―	90.27%